News

All the latest developments
from the institute

Scientist In Lab 2 Shutterstock Gorodenkoff

Disappointment as phase 3 trials for Alzheimer's drug ganteneurumab show no clinical benefit

In a press release today, pharmaceutical company Roche announced results from its phase 3 trials of immunotherapy drug ganteneurumab. The results show that the drug failed to slow cognitive decline in people with early-stage Alzheimer's disease.

Read Article
Chan Zuckerberg Banner Logo

Three UK DRI researchers awarded major Chan Zuckerberg Initiative funding for collaborative projects

Dr Soyon Hong, Dr Tim Bartels, and Prof Adrian Isaacs, all from UK DRI at UCL, have each been awarded further funding from the Chan Zuckerberg Initiative (CZI), for phase 2 of the organisation’s Collaborative Pairs Programme.

Read Article
Big Timages032 Copy

UK DRI joins call to place medical and health research at the heart of economic plans

Ahead of the government’s Autumn Statement, the UK DRI has joined a call led by the Academy of Medical Sciences, for the Chancellor to place medical and health research at the heart of plans for growth.

Read Article
Connectome 2022 Prize Banner 2

First recipients of UK DRI Recognition Prizes announced at Connectome 2022

For the 5th anniversary of the UK DRI, we introduced a series of special prizes to recognise the efforts and achievements of staff across the Institute over the past year. The Directors awarded certificates and personal awards during the conclusion to Connectome 2022, highlighting those individuals excelling in the categories of computational reproducibility, 3R’s, publications, posters and engagement.

Read Article
Oligodendrocyte Owen Red 1

Macroglia: introducing the UK DRI’s newest research theme

When thinking about the cells that are involved in neurodegenerative diseases, it is easy to zero in on neurons – the fundamental units of the brain that receive and transmit sensory information. But there is strong evidence to indicate that other cells are also involved in the development and progression of dementia. Among them are macroglia cells; the focus of the UK DRI’s newest research theme.

Read Article
Dna Helix Billion Photos Shutterstock 1665847021

Scientists reveal new insight into how Alzheimer’s risk gene may cause disease

Researchers have uncovered a new biological pathway that could be linked to Alzheimer’s disease, in a study led by Prof Paul Elliott (UK DRI at Imperial). The findings, published in the journal Proceedings of the National Academy of Sciences (PNAS), provide new insight into the underlying mechanisms of the disease, and could offer targets for future drug discovery.

Read Article
Rs12244

Discussing diversity in dementia research

How health inequalities are impacting people with dementia, and how research can help to address this was the subject of a lively webinar hosted by the UK DRI on Thursday 20 October.

Read Article
Yu Ye Banner 2

‘Cell-penetrating’ proteins implicated in Parkinson’s and dementia with Lewy bodies

Small, aggregated proteins capable of entering cells have been shown to cause distinctive toxic effects in Parkinson’s disease and dementia with Lewy bodies, according to a new study led by Dr Yu Ye (UK DRI at Imperial). The findings, published in the journal Proceedings of the National Academy of Sciences (PNAS), offer useful insight into the underlying mechanisms of these diseases, and highlight potential future targets for disease detection and therapeutic intervention.

Read Article
Us Nam Logo Banner

UK DRI Director elected to the U.S. National Academy of Medicine

Prof Bart De Strooper, UK DRI Director, has today been elected to the U.S. National Academy of Medicine (NAM), for his work in understanding the mechanisms of Alzheimer’s disease, ‘in an unrelenting search for therapeutic targets that can help patients’.

Read Article
220427 Dementia Dri Labmain 013 Copy

Major donation to accelerate Alzheimer's disease research at the UK DRI at Imperial

We are delighted to announce a generous £7.5 million gift from the Michael Uren Foundation that will drive forward four experimental research projects at the UK DRI, aiming to improve diagnosis of Alzheimer’s disease and develop effective new avenues for treatment.

Read Article
220427 Dementia Dri Labmain 006

Translation award: catching up with past recipients of the UK DRI’s innovation scheme

Launched in March 2021, the UK DRI Translation Award programme was established to kick start the early development of projects with high translational potential, bringing us closer to new technologies and treatments for dementia. We caught up with a selection of the successful past recipients to discover the impact these awards have had on their research.

Read Article
Scientist In Lab Shutterstock Gorodenkoff

Milestone in search for Alzheimer’s treatment as lecanemab slows cognitive decline in phase 3 trial

Today the pharmaceutical company Eisai, in collaboration with Biogen, has announced positive results from its phase 3 trial of lecanemab for the treatment of Alzheimer’s disease. Eisai reports, using a numeric scale to quantify severity of symptoms, that the drug slowed rate of cognitive decline by 27% compared with a placebo.

Read Article
Fondation Recherche Ad Logo Banner

Prof Nick Fox awarded Grand Prix Européen 2022

We are delighted to announce that Prof Nick Fox (UK DRI at UCL) has been awarded the European Grand Prix 2022 by the French Alzheimer Research Foundation.

Read Article
Better Ageing Older People

How will dementia diagnosis and treatment change in the next 10 years?

Every year, the number of people with dementia increases, with estimates suggesting more than 1 million people in the UK will be living with the condition by 2030. As this figure increases, there is an even greater need for breakthroughs in developing treatments and improving lives. So how close are we to new therapeutics? And what innovations will help us get there? This World Alzheimer's Day, we asked UK DRI researchers for their predictions on what we can expect over the next decade, and where they see the most promising advances.

Read Article
Axonal Transport Video Orange

Research reveals new insights into disease mechanisms underlying ALS

A new study led by Prof. Giampietro Schiavo (UK DRI at UCL) has uncovered why certain types of motor neurons are differentially affected in amyotrophic lateral sclerosis (ALS). The findings, published in the journal Acta Neuropathologica Communications, could open up new avenues for drug discovery and treatments for this disease.

Read Article
Rs8166 Copy

UK DRI report urges action to reduce health inequalities in dementia

Today, the UK DRI published a new report, detailing the impact of scientific research on health inequalities for people affected by dementia. As the report launches at the start of World Alzheimer’s Month, the UK DRI is urging the Government to prioritise funding for scientific innovation, to facilitate larger dementia trials, remove barriers that stop people taking part in research and close the gap on health inequalities.

Read Article
Cure Nd Ecr May 22 112

CURE-ND: European partners unite in scientific and political spheres

The first half of the 2022 saw the European alliance for neurodegenerative research, CURE-ND, come together for a London meeting of early career researchers (ECRs), a networking and showcase event at Europe’s biggest neuroscience conference and a collective request for urgent clarity and action surrounding the UK’s association with Horizon Europe.

Read Article
Blood Vessel Michelangelus Shutterstock

New study reveals genetic link between heart health and vascular dementia

A new study led by Prof Paul Matthews (UK DRI at Imperial) has identified a genetic link between damage to the main blood vessels of the heart, and brain small vessel disease, a common cause of vascular dementia.

Read Article
Rubinsztien Banner

Researchers identify way to enhance breakdown of misfolded proteins in neurodegenerative disease

A new study led by Prof David Rubinsztein (UK DRI at Cambridge) has identified a way to enhance the cell’s ability to clear away misfolded proteins, such as those implicated in neurodegenerative diseases like Alzheimer’s.

Read Article
Driarrows Synergy A3 Design Shutterstock Copy

OVID Health: the UK has a genuinely rich dementia research ecosystem

In a new blog post this week, Roudie Shafie, a partner at OVID Health, argues that while beating dementia is a “Herculean task”, the UK has all the necessary components in its research ecosystem to achieve real results.

Read Article

Founding funders

Latest tweets from @UKDRI

RT @suvankarpal: Congratulations to the formidable @drarpan100 for winning the ECR platform presentation prize at the #CUREND clinical work…
03 Feb 2023 17:11

RT @DrArpan100: Absolutely super, comprehensive talk by @DrNatalieRyan @drcionucl @UKDRI on her research into familial Alzheimer's dementia…
03 Feb 2023 12:09